<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03382769</url>
  </required_header>
  <id_info>
    <org_study_id>CLTD5693</org_study_id>
    <nct_id>NCT03382769</nct_id>
  </id_info>
  <brief_title>Hearing Loss in Older Adults Study</brief_title>
  <official_title>Hearing Loss in Older Adults: A Randomized Controlled Trial of Immediate Versus Delayed Cochlear Implantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cochlear</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CogState Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cochlear</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, 1:1 randomized controlled trial of immediate versus delayed cochlear&#xD;
      implantation (CI) on hearing handicap, communicative function, loneliness, mental wellbeing,&#xD;
      and cognitive functioning. Participants are randomized 1:1 to an immediate cochlear implant&#xD;
      intervention group versus a hearing aid control intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Early terminated due to COVID-19 public health emergency, with a patient population in&#xD;
    vulnerable populations (older adults) seeking cochlear implantation as elective Standard of&#xD;
    Care.&#xD;
  </why_stopped>
  <start_date type="Actual">March 27, 2019</start_date>
  <completion_date type="Actual">January 4, 2020</completion_date>
  <primary_completion_date type="Actual">January 4, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hearing Handicap</measure>
    <time_frame>6 months after enrollment</time_frame>
    <description>Assessment of the impact of cochlear implantation versus continued hearing aid use on hearing handicap as measured on the Speech, Spatial, and Qualities of Hearing (SSQ12)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hearing Loss, Sensorineural</condition>
  <condition>Hearing Loss, Bilateral</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A will consist of 30 individuals who are candidates for cochlear implantation. They will be unilaterally implanted immediately after initial study testing has been completed and then be followed for 12 months after device activation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B will consist of 30 individuals who are candidates for cochlear implantation. They will continue to wear hearing aids after enrolling in the study and then be unilaterally implanted and followed for 6 more months after device activation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cochlear implantation</intervention_name>
    <description>Unilateral implantation with a commercially approved Nucleus cochlear implant</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Community-dwelling&#xD;
&#xD;
          -  Proficient in English&#xD;
&#xD;
          -  Oral communicator&#xD;
&#xD;
          -  PTA (500, 1000 &amp; 2000 Hz) ≥ 70 dB HL hearing loss duration ≥1 and no more than 30&#xD;
             years&#xD;
&#xD;
          -  Active daily hearing aid users&#xD;
&#xD;
          -  HHIE-S score greater than or equal to 24&#xD;
&#xD;
          -  MoCA score greater than or equal to 20&#xD;
&#xD;
          -  Post-linguistic onset sensorineural hearing loss and meet applicable FDA and/or&#xD;
             Medicare candidacy criteria for cochlear implantation&#xD;
&#xD;
          -  Willing to consent for the study, to be randomized to either group, to utilize bimodal&#xD;
             hearing for the duration of the trial (if clinically appropriate), and follow the&#xD;
             study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prelingual or perilingual severe-to-profound hearing loss&#xD;
&#xD;
          -  Previous cochlear implantation in either ear&#xD;
&#xD;
          -  Hearing loss of neural or central origin&#xD;
&#xD;
          -  Permanent conductive hearing impairment (e.g. otosclerosis)&#xD;
&#xD;
          -  Medical, audiological, or psychological conductions that might contraindicate&#xD;
             participation in the clinical investigation&#xD;
&#xD;
          -  Self reported disability in 2 or more activities of daily living&#xD;
&#xD;
          -  Vision impairment worse than 20/40 on a near vision card&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David N Cade, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Cochlear</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Center for Neurosciences</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>House Ear Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary of Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Health</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
    <mesh_term>Hearing Loss, Bilateral</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

